Alvotech (ALVO) EBT Margin (2022 - 2026)
Alvotech's (ALVO) quarterly EBT Margin came in at 121.92% in Q2 2026, down 13174.0% on a YoY basis from N/an in Q2 2025, and down 6428.45% quarter-over-quarter from 1.93% in Q1 2026.
Powered by 
Analysis
Alvotech (ALVO) EBT Margin (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported EBT Margin for 5 consecutive years, with 121.92% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 13174.0% year-over-year to 121.92%; the trailing twelve-month figure through Jun 2026 stood at 69.58% (down 2764.0% YoY), and the FY2025 full-year result was 49.35%, up 12891.0% from the prior year.
- EBT Margin retreated to 121.92% in Q2 2026 per ALVO's latest filing, from 1.93% in the prior quarter.
- Across five years, EBT Margin topped out at 2464.63% in Q2 2023 and bottomed at 14029.68% in Q4 2022.
- Historically, EBT Margin has averaged 1411.55% across 5 years, with a median of 80.89% in 2026.
- The sharpest annual moves came in 2023 and 2024: EBT Margin soared 1058479 bps in 2023, then slumped 232104 bps in 2024.
- Over 5 years, EBT Margin stood at 14029.68% in 2022, then jumped by 75 bps to 3444.89% in 2023, then soared by 90 bps to 330.08% in 2024, then soared by 115 bps to 50.18% in 2025, then slumped by 343 bps to 121.92% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 121.92%, 1.93%, and 50.18% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -10.99% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -1.70% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 6.85% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 8.92% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 12.20% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -121.92% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 13.94% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 20.96% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 11.27% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -121.92% |
| Mar 31, 2026 | 1.93% |
| Dec 31, 2025 | 50.18% |
| Sep 30, 2025 | -844.90% |
| Jun 30, 2025 | 9.82% |
| Mar 31, 2025 | 85.00% |
| Dec 31, 2024 | -330.08% |
| Sep 30, 2024 | -39.85% |
| Jun 30, 2024 | 143.59% |
| Mar 31, 2024 | -1,811.48% |
| Dec 31, 2023 | -3,444.89% |
| Aug 31, 2023 | -601.84% |
| Jun 30, 2023 | 2,464.63% |
| Dec 31, 2022 | -14,029.68% |
| Aug 31, 2022 | -5,125.74% |
| Jun 30, 2022 | 1,010.46% |